MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
PR Newswire

News of the day

Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products

18th November 2009 IRVINE, California, November 18 /PRNewswire/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Lyon, France-based Uni.H.A., one of the largest healthcare Group Purchasing Organizations (GPO) in France, has signed a multi-year purchasing agreement for "gold standard" Masimo SET(R) pulse oximeters. The agreement offers preferred contract pricing to Uni.H.A.'s 53 member hospitals and provides for more... more

Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries

17th November 2009 HAYWARD, California, November 17 /PRNewswire/ -- Zyomyx, Inc., a leader in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-care (POC) technology was selected by Imperial College London's CD4 Initiative as the best-performing POC test method for measuring CD4 T-cell count in HIV/AIDS patients. Zyomyx's CD4 assay is now the only remaining POC product being supported by the CD4 Initiative. With this announcement, Zyomyx is currently entering the commercial... more

Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health

4th November 2009 PETERSBURG, Virginia, November 4 /PRNewswire/ -- Star Scientific, Inc. (Nasdaq: STSI) announced today that the company plans to introduce the CigRx(TM) nutraceutical product developed by its subsidiary, Rock Creek Pharmaceuticals, for worldwide marketing and sales in partnership with inVentiv Health, Inc. (Nasdaq: VTIV). inVentiv Health offers a complete range of commercialization solutions for every stage of the product lifecycle, in a range of healthcare categories that includes nutraceutical... more
Licensing/Marketing Agreements RSS feed

PR Newswire search

Search the PR Newswire by keyword. Alternatively our advanced search allows you to query by category.
 

Category

To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Browse by category

More recent news

AMT Starts Development LPLChip(TM) With Progenika
29th October 2009 AMSTERDAM, October 29 /PRNewswire/ -- Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement...

Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
28th October 2009 BAD HOMBURG, Germany and LACHEN, Switzerland, October 28 /PRNewswire/ -- Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius...

Jordan Unveils State of the Art Healthcare Technology in Hospital Trial
27th October 2009 AMMAN, Jordan, October 27 /PRNewswire/ -- The Hashemite Kingdom of Jordan, in a public demonstration today hosted by His Majesty King Abdullah II, provided a stunning look at the new integrated...

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
21st October 2009 CAMBRIDGE, Massachusetts, October 21 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA)...

Thermo Fisher Scientific's Biomarker B-R-A-H-M-S PCT (Procalcitonin) Included in S3 Guidelines
19th October 2009 HENNIGSDORF, Germany, October 19 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its biomarker, B-R-A-H-M-S PCT (procalcitonin), has been...

Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
13th October 2009 PHILADELPHIA, October 13 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc....

The Queensland Facility for Advanced Bioinformatics Selects IPA in Multi-Year Deal for Systems Biology Effort
6th October 2009 REDWOOD CITY, California, October 6 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, and Millennium Science, Ingenuity Systems'...

Onglyza(R) (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
5th October 2009 PARIS and LONDON, October 5 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) (LSE: AZN) announced today that the European Commission has granted...

Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union
25th September 2009 PARIS, September 25 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA)...

Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy (1,2)
24th September 2009 FRIMLEY, England, September 24 /PRNewswire/ -- Afinitor(R) (everolimus) has recently been licensed for the treatment of advanced kidney cancer after failure of treatments which prevent the growth...

Novasep Gains SafeBridge(R) "Potent Compound Safety Certification" for its Le Mans Facility
17th September 2009 POMPEY, France, September 17 /PRNewswire/ -- Novasep is pleased to announce that its site in Le Mans - France, specialized in the development and manufacturing of Highly Potent Active Pharmaceutical...

Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
15th September 2009 FREISING-WEIHENSTEPHAN, Germany, September 15 /PRNewswire/ -- Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris'...

Forest Laboratories UK Ltd Submits Marketing Authorisation Application for the First Dry Powder Inhalation Antibiotic for Cystic Fibrosis Patients
15th September 2009 LONDON, September 15 /PRNewswire/ -- Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest Laboratories Inc) announced that following the successful completion of its pan-European...

Accumetrics, Inc. Forms Partnership With Grifols as Its Distributor in Spain, Portugal and Chile
2nd September 2009 SAN DIEGO, September 2 /PRNewswire/ -- Accumetrics, Inc. has announced the signing of a new exclusive distribution agreement for its VerifyNow(R) System in Spain, Portugal and Chile with Grifols...

Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
27th August 2009 MAIDENHEAD, England, August 27 /PRNewswire/ -- Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of...

Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website
11th August 2009 REDWOOD CITY, California, August 11 /PRNewswire/ -- Ingenuity Systems today announced that BD Biosciences, a segment of BD (Becton, Dickinson and Company), is integrating Ingenuity's Knowledge...

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4th August 2009 PALO ALTO, California, August 4 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide...

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us